Cancer and IgE

Introducing the Concept of AllergoOncology

  • Manuel L. Penichet
  • Erika Jensen-Jarolim

Table of contents

  1. Front Matter
    Pages i-ix
  2. Erika Jensen-Jarolim, Manuel L. Penichet
    Pages 1-11
  3. Gernot Achatz, Gertrude Achatz-Straussberger, Stefan Feichtner, Sebastian Koenigsberger, Stefan Lenz, Doris Peckl-Schmid et al.
    Pages 13-36
  4. Maria A. Curotto de Lafaille, Juan J. Lafaille
    Pages 37-46
  5. Otoniel Martínez-Maza, Alan Duane Moreno, Wendy Cozen
    Pages 79-136
  6. Anna Wasiuk, Victor C. de Vries, Elizabeth C. Nowak, Randolph J. Noelle
    Pages 137-158
  7. Tracy R. Daniels, José A. Rodríguez, Elizabeth Ortiz-Sánchez, Gustavo Helguera, Manuel L. Penichet
    Pages 159-183
  8. Sophia N. Karagiannis, Frank O. Nestle, Hannah J. Gould
    Pages 185-213
  9. Elisa A. Nigro, Antonio G. Siccardi, Luca Vangelista
    Pages 215-229
  10. Erika Jensen-Jarolim, Diana Mechtcheriakova, Isabella Pali-Schoell
    Pages 231-254
  11. Ljubov Simson, Julia I. Ellyard, Christopher R. Parish
    Pages 255-275
  12. Back Matter
    Pages 277-287

About this book

Introduction

Allergies are caused by a person’s own IgE antibodies directed against innocuous antigens like pollen or house dust mites. Interestingly, several studies have examined the relation between allergies or level of IgE and malignancies and have found an inverse association suggesting a natural role of IgE in cancer immunosurveillance. Is it thus possible that IgE immunoglobulins could have a beneficial function against cancer besides their harmful function in allergy? If so, can we exploit this beneficial function for the development of new cancer therapies? Could oncologists learn from allergists and vice versa? This book attempts to explore step by step these interesting questions, opening a novel science field: AllergoOncology.

AllergoOncology by definition aims to reveal the function of IgE-mediated immune responses against cancer cells in order to enhance the understanding of its biology and to develop novel IgE-based treatment options against malignant diseases. Cancer and IgE: Introducing the Concept of AllergoOncology opens new avenues towards IgE antibodies as key effector molecules able to confer protection against cancer development and progression. This affinity-matured class of antibody, belonging to Th2-mediated immunity, uses an exquisite panel of potent effector cells which can eradicate malignant cells. Importantly, IgE is also capable of binding to professional antigen presenting cells thereby enhancing the presentation of cancer antigens and leading to a significant anti-tumor immune response. Based on its anti-tumor efficacy, which has been shown in vitro and in preclinical models, IgE can be potentially used in human in the context passive and active cancer immunotherapy. In summary, this book, which is the first of its class, is a comprehensive volume about the evolving new field AllergoOncology.

Keywords

Allergie Antigen allergy diseases immunotherapy infectious disease mortality prevention prostate cancer tumor tumor surveillance vaccine

Editors and affiliations

  • Manuel L. Penichet
    • 1
  • Erika Jensen-Jarolim
    • 2
  1. 1.David Geffen School of MedicineUniversity of California, Los AngelesLos AngelesU.S.A.
  2. 2.Zentrum für Physiologie,Medizinische Universität WienWienAustria

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-60761-451-7
  • Copyright Information Humana Press 2010
  • Publisher Name Humana Press
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-1-60761-450-0
  • Online ISBN 978-1-60761-451-7
  • About this book